Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.5 EUR | +3.91% | -4.66% | +81.05% |
Apr. 05 | Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications | MT |
Mar. 28 | Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | 51.33M 55.53M | Sales 2025 * | 58.9M 63.72M | Capitalization | 68.14M 73.71M |
---|---|---|---|---|---|
Net income 2024 * | 1M 1.08M | Net income 2025 * | 3M 3.25M | EV / Sales 2024 * | 1.12 x |
Net cash position 2024 * | 10.53M 11.39M | Net cash position 2025 * | 10.63M 11.5M | EV / Sales 2025 * | 0.98 x |
P/E ratio 2024 * |
52.2
x | P/E ratio 2025 * |
18.5
x | Employees | 177 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98% |
Latest transcript on Apontis Pharma AG
1 day | +3.91% | ||
1 week | -4.66% | ||
Current month | +4.12% | ||
1 month | +4.12% | ||
3 months | +36.08% | ||
6 months | +116.62% | ||
Current year | +81.05% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | - | |
Director of Finance/CFO | - | 21-12-31 | |
Olaf Randerath
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Edin Hadzic
BRD | Director/Board Member | 53 | 20-12-31 |
Olaf Elbracht
BRD | Director/Board Member | 59 | 20-12-31 |
Chairman | 51 | 20-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-30 | 8.6 | +5.13% | 4 255 |
24-05-29 | 8.18 | -2.39% | 3,282 |
24-05-28 | 8.38 | -4.56% | 11,175 |
24-05-27 | 8.78 | -0.90% | 5,178 |
24-05-24 | 8.86 | -1.77% | 2,937 |
Delayed Quote Xetra, May 30, 2024 at 07:30 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+81.05% | 73.7M | |
+39.22% | 731B | |
+32.29% | 586B | |
-7.85% | 348B | |
+15.48% | 319B | |
-0.12% | 273B | |
+13.45% | 235B | |
+7.43% | 202B | |
-6.95% | 203B | |
-3.37% | 158B |
- Stock Market
- Equities
- APPH Stock